Skip to main content
SpringerLink
Log in

Aggressive B-Cell Lymphomas

  • Chapter
  • First Online:
PET/CT in Lymphomas

  • 1090 Accesses

Abstract

Aggressive B-cell lymphomas include diffuse large B-cell lymphomas not otherwise specified (DLBCL NOS), other subtypes of DLBCL [T-cell/histiocyte-rich LBCL, DLBCL leg type, primary DLBCL of the central nervous system (CNS), and Epstein-Barr virus (EBV+) DLBCL of the elderly], “other neoplasms of large B cells,” mainly including primary mediastinal large B-cell lymphoma (PMLBCL) and several other very uncommon entities (see Chap. 4), and cases with borderline features between DLBCL and Hodgkin lymphoma (HL) or DLBCL and Burkitt lymphoma, the so-called gray-zone lymphomas. This chapter is focused to DLBCL NOS and other subtypes of DLBCL (except of primary CNS, which is covered in Chap. 13) as well as to PMLBCL, i.e., to the most frequent entities classified in aggressive B-cell lymphomas.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 129.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Lister TA et al (2014) Recommendations for the initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32:3059–3067

    Article  PubMed  Google Scholar 

  2. Barrington SF, Mikhaeel GN, Kostakoglu L, Meignan M, Hutchings M, Müeller SP et al (2014) Role of imaging in the staging and response assessment of lymphoma: Consensus of the International Conference on Malignant Lymphomas Imaging Working Group. J Clin Oncol 32:3048–3058

    Article  PubMed  Google Scholar 

  3. Vassilakopoulos TP, Prassopoulos V, Rondogianni P, Chatziioannou S, Konstantopoulos K, Angelopoulou MK (2015) Role of FDG-PET/CT in staging and first-line treatment of Hodgkin and aggressive B-cell lymphomas. Memo 8:105–114

    Google Scholar 

  4. Sehn LH, Klasa R, Shenkier T, Villa D, Slack GW, Gascoyne RD et al (2013) Long-term experience with PET-guided consolidative radiation therapy (XRT) in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) treated with R-CHOP. Hematol Oncol 31(S1):137 (abstr 123)

    Google Scholar 

  5. Pfreundschuh M, Trumper L, Osterborg A et al (2006) CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 7:379–391

    Article  CAS  PubMed  Google Scholar 

  6. Pfreundschuh M, Schubert J, Ziepert M et al (2008) Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomized controlled trial (RICOVER-60). Lancet Oncol 9:105–116

    Article  CAS  PubMed  Google Scholar 

  7. Vassilakopoulos TP, Pangalis GA, Katsigiannis A et al (2012) Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone with or without radiotherapy in primary mediastinal large B-cell lymphoma: the emerging standard of care. Oncologist 17:239–249

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Martelli M, Ceriani L, Zucca E, Zinzani PL, Ferreri AJ, Vitolo U et al (2014) [18F] fluorodeoxyglucose positron emission tomography predicts survival after chemoimmunotherapy for primary mediastinal large B-cell lymphoma: results of the International Extranodal Lymphoma Study Group IELSG-26 study. J Clin Oncol 32:1769–1775

    Article  PubMed  Google Scholar 

  9. Sehn LH, Scott DW, Chhanabhai M et al (2011) Impact of concordant and discordant bone marrow involvement on outcome in diffuse large B-cell lymphoma treated with R-CHOP. J Clin Oncol 29:1452–1457

    Article  PubMed  Google Scholar 

  10. Paone G, Itti E, Haioun C et al (2009) Bone marrow involvement in diffuse large B-cell lymphoma: Correlation between FDG-PET uptake and type of cellular infiltrate. Eur J Nucl Med Mol Imaging 36:745–750

    Article  PubMed  Google Scholar 

  11. Adams HJA, Kwee TC, Finjnheer R, Dubois SV, Nievelstein AJR, de Klerk JMH (2014) Bone marrow 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography cannot replace bone marrow biopsy in diffuse large B-cell lymphoma. Am J Hematol 89:726–731

    Article  CAS  PubMed  Google Scholar 

  12. Hong J, Lee Y, Park Y et al (2012) Role of FDG-PET/CT in detecting lymphomatous bone marrow involvement in patients with newly diagnosed diffuse large B-cell lymphoma. Ann Hematol 91:687–695

    Article  CAS  PubMed  Google Scholar 

  13. Cerci JJ, Gyorke T, Fanti S, Paez D, Meneghetti JC, Redondo F et al (2014) Combined PET and biopsy evidence of marrow involvement improves prognostic prediction in diffuse large B-cell lymphoma. J Nucl Med 55:1591–1597

    Article  PubMed  Google Scholar 

  14. Berthet L, Cochet A, Kanoun S, Berriolo-Riedinger A, Humbert O, Toubeau M et al (2013) In newly diagnosed diffuse large B-cell lymphoma, determination of bone marrow involvement with 18F-FDG PET/CT provides better diagnostic performance and prognostic stratification than does biopsy. J Nucl Med 54:1244–1250

    Article  CAS  PubMed  Google Scholar 

  15. Khan AB, Barrington SF, Mikhaeel NG, Hunt AA, Cameron L, Morris T et al (2013) PET-CT staging of DLBCL accurately identifies and provides new insight into the clinical significance of bone marrow involvement. Blood 122:61–67

    Article  CAS  PubMed  Google Scholar 

  16. Adams HJA, Kwee TC (2015) Do not abandon the bone marrow biopsy yet in diffuse large B-cell lymphoma. J Clin Oncol 33:1217

    Google Scholar 

  17. Meignan M, Itti E, Gallamini A, Younes A (2015) FDG PET/CT imaging as a biomarker in lymphoma. Eur J Nucl Med Mol Imaging 42(4):623–633

    Google Scholar 

  18. Sasanelli M, Meignan M, Haioun C, Berriolo-Riedinger A, Casasnovas RO, Biggi A et al (2014) Pretherapy metabolic tumor volume is an independent predictor of outcome in diffuse large B-cell lymphoma. Eur J Nucl Med Mol Imaging 41:2017–2022

    Article  CAS  PubMed  Google Scholar 

  19. Song MK, Chung JS, Shin HJ, Lee SM, Lee SE, Lee HS et al (2012) Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement. Ann Hematol 91:697–703

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Kim TM, Paeng JC, Chun IK, Keam B, Jeon YK, Lee SH et al (2013) Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the international prognostic index for patients with diffuse large B cell lymphoma. Cancer 119:1195–1202

    Article  CAS  PubMed  Google Scholar 

  21. Ceriani L, Martelli M, Zinzani PL et al (2015) Utility of baseline 18FDG PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. Blood 126(8):950–956

    Google Scholar 

  22. Dupuis J, Itti E, Rahmouni A, Hemery F et al (2009) Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 20:503–507

    Article  CAS  PubMed  Google Scholar 

  23. Dabaja BS, Phan J, Mawlawi O, Medeiros LJ, Etzel C, Liang FW et al (2013) Clinical implications of positron emission tomography-negative residual computed tomography masses after chemotherapy for diffuse large B-cell lymphoma. Leuk Lymphoma 54:2631–2638

    Article  CAS  PubMed  Google Scholar 

  24. Vassilakopoulos TP, Kanellopoulos A, Papageorgiou S, Pangalis GA, Anastasopoulou A, Moschogianni M et al (2014) Clinical implications and prognostic significance of positron emission tomography (PET/CT) in patients with diffuse large B-cell lymphoma (DLBCL) after R-CHOP chemoimmunotherapy. Hematol J 99(Suppl 1):702 (abstr. 1831)

    Google Scholar 

  25. Thomas A, Gingrich RD, Smith BJ et al (2010) 18-fluoro-deoxyglucose positron emission tomography report interpretation as predictor of outcome in diffuse large B-cell lymphoma including analysis of “indeterminate” reports. Leuk Lymphoma 51:439–446

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Pregno P, Chiappella A, Bello M, Botto B, Ferrero S, Franceschetti S et al (2012) Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. Blood 119:2066–2073

    Article  CAS  PubMed  Google Scholar 

  27. Mamot C, Klingbiel D, Hitz F et al (2015) Final results of a prospective evaluation of the predictive value of interim positron emission tomography in patients with diffuse large B-cell lymphoma treated with R-CHOP-14 (SAKK 38/07). J Clin Oncol 33:2523–2529

    Google Scholar 

  28. Vassilakopoulos TP, Pangalis GA, Chatziioannou S et al (2016) PET/CT in patients with primary mediastinal large B-cell lymphoma responding to Rituximab-CHOP: an analysis of 106 patients regarding prognostic significance and implications for subsequent radiotherapy. Leukemia 30:238–242

    Google Scholar 

  29. Dunleavy K, Pittaluga S, Maeda LS et al (2013) Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma. N Engl J Med 368:1408–1416

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Filippi AR, Piva C, Giunta F et al (2013) Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy. Int J Radiat Oncol Biol Phys 87:311–316

    Article  CAS  PubMed  Google Scholar 

  31. Ceriani L, Martelli M, Zinzani P et al (2015) Use of the Lugano classification criteria for PET/CT assessment of primary mediastinal B-cell lymphoma after immunochemotherapy and irradiation in the IELSG-26 study. Hematol Oncol 33(S1):143 (abstr. 081)

    Google Scholar 

  32. Vassilakopoulos TP, Pangalis GA, Polliack A (2015) A “PET” topic in primary mediastinal large B-cell lymphoma: positive or negative, and how to handle it in the end. Leuk Lymphoma 56:3–5

    Article  PubMed  Google Scholar 

  33. Martelli M, Zucca E, Gospodarowicz M, Johnson PWM, Ricardi U (2013) A randomized, multicentre, two-arm phase III comparative study assessing the role of mediastinal radiotherapy after rituximab-containing chemotherapy regimens to patients with newly diagnosed primary mediastinal large B-cell lymphoma (PMLBCL): the IELSG-37 study. Hematol Oncol 31(S1):140

    Google Scholar 

  34. Itti E, Juweid ME, Haioun C et al (2010) Improvement of early 18F-FDG-PET interpretation in diffuse large B-cell Lymphoma: importance of the reference background. J Nucl Med 51:1857–1862

    Article  PubMed  Google Scholar 

  35. Moskowitz CH, Schoder H, Teruya-Feldstein J et al (2010) Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 28:1896–1903

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Avigdor A, Sirotkin T, Kedmi M, Ribakovsy E, Berkowicz M, Davidovitz Y et al (2014) The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma. Ann Hematol 93:1297–1304

    Article  CAS  PubMed  Google Scholar 

  37. Moskowitz C, Hamlin PA, Maragulia J, Meikle J, Zelenetz AD (2010) Sequential dose-dense RCHOP followed by ICE consolidation (MSKCC protocol 01–142) without radiotherapy for patients with primary mediastinal large B-cell lymphoma. Blood 116:abstr 420

    Google Scholar 

  38. Horning SJ, Juweid ME, Schoeder H et al (2010) Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study. Blood 115:775–777

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Meignan M, Gallamini A, Itti E, Barrington S, Haioun C, Polliack A (2012) Report on the third international workshop on interim positron emission tomography in lymphoma held in Menton, France, 26–27 September 2011 and Menton 2011 consensus. Leuk Lymphoma 53:1876–1881

    Article  PubMed  Google Scholar 

  40. Carr R, Fanti S, Paez D, Cerci J, Gyorke T, Redondo F et al (2014) Prospective international cohort study demonstrates inability if interim PET to predict treatment failure in diffuse large B-cell lymphoma. J Nucl Med 55:1936–1944

    Article  PubMed  Google Scholar 

  41. Itti E, Meignan M, Berriolo-Riedinger A, Biggi A, Cashen AF, Verra P et al (2013) An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax. Eur J Nucl Med Mol Imaging 40:1312–1320

    Article  PubMed  Google Scholar 

  42. Casasnovas RO, Meignan M, Berriolo-Riedinger A et al (2011) SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. Blood 118:37–43

    Article  CAS  PubMed  Google Scholar 

  43. Duehrsen U, Hüttmann A, Müller S, Hertenstein B, Kotzerke J, Mesters R et al (2014) Positron emission tomography (PET) guided therapy of aggressive lymphomas – a randomized controlled trial comparing different treatment approaches based on interim PET results (PETAL Trial). Blood. (ASH Annual Meeting Abstracts) 124:Abstract 391

    Google Scholar 

  44. Swinnen LJ, Li H, Quon A, Gascoyne RD, Ranheim EA, Hong F et al (2013) Response-adapted therapy and predictive value of mid-treatment PET scanning for diffuse large B-cell lymphoma. ECOG study E3404. Hematol Oncol 31(S1):138 (abstr. 126). Hematol Oncol. 2013; 31(S1): 101 (abstr. 016)

    Google Scholar 

  45. Sehn LH, Hardy ELG, Gill KK, Al-Tourah AJ, Shustik J, Macpherson MA et al (2014) Phase 2 trial of interim PET scan-tailored therapy in patients with advanced stage diffuse large B-cell lymphoma (DLBCL) in British Columbia (BC). Blood. (ASH Annual Meeting Abstracts) 124:Abstract 392

    Google Scholar 

  46. Recher C, Coiffier B, Haioun C et al (2011) Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial. Lancet 378:1858–1867

    Article  CAS  PubMed  Google Scholar 

  47. Cheson BD, Pfistner B, Juweid ME et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586

    Article  PubMed  Google Scholar 

  48. Juweid ME, Stroobants S, Hoekstra OS et al (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578

    Article  PubMed  Google Scholar 

  49. Wirk B (2010) Sarcoid reactions after chemotherapy for Hodgkin’s lymphoma. Clin Med Insights Case Rep 3:21–25

    Article  PubMed  PubMed Central  Google Scholar 

  50. Papageorgiou SG, Sachanas S, Pangalis GA et al (2014) Gastric involvement in patients with primary mediastinal large B-cell lymphoma. Anticancer Res 34:6717–6723

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Haematology, National and Kapodistrian University of Athens, School of Medicine, Laikon General Hospital, 17, Agiou Thoma street, Goudi, Athens, 11527, Greece

    Theodoros P. Vassilakopoulos MD & Vasileios I. Telonis MD

  2. Department of Nuclear Medicine and PET/CT, HYGEIA Hospital, Athens, Kifissias and Erythrou Staurou 4, Maroussi, 15123, Greece

    Vassilios K. Prassopoulos MD & Effimia P. Vrakidou

  3. Department of Nuclear Medicine and PET/CT, Evangelismos General Hospital, Athens, 45-47 Ipsilantou Street, Athens, 11576, Greece

    Phoivi Rondogianni MD, FENMB

  4. Centre for Clinical and Translational Research, Biomedical Research Foundation of the Academy of Athens, 4 Soranou Ephessiou Street, Athens, 11527, Greece

    Sofia N. Chatziioannou MD

Authors
  1. Theodoros P. Vassilakopoulos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Vassilios K. Prassopoulos MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Phoivi Rondogianni MD, FENMB
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sofia N. Chatziioannou MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Vasileios I. Telonis MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Effimia P. Vrakidou
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Theodoros P. Vassilakopoulos MD .

Editor information

Editors and Affiliations

  1. Hygeia and Mitera Hospital, Athens, Greece

    John A. Andreou

  2. Hygeia Hospital, Medical Oncology Department, Athens, Greece

    Paris A. Kosmidis

  3. National & Kapodistrian University, Radiology (emeritus), Athens, Greece

    Athanasios D. Gouliamos

Rights and permissions

Reprints and permissions

Copyright information

© 2016 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Vassilakopoulos, T.P., Prassopoulos, V.K., Rondogianni, P., Chatziioannou, S.N., Telonis, V.I., Vrakidou, E.P. (2016). Aggressive B-Cell Lymphomas. In: Andreou, J., Kosmidis, P., Gouliamos, A. (eds) PET/CT in Lymphomas. Springer, Cham. https://doi.org/10.1007/978-3-319-27380-8_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-27380-8_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-27378-5

  • Online ISBN: 978-3-319-27380-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation